Lactobacillus acidophilus and its application in wound healing
By applying Lactobacillus acidophilus JZG-1 and its metabolites directly to the wound, the problems of easy infection and slow healing of severe burn wounds were solved, achieving effective antibacterial and wound healing promotion, and reducing scar formation.
Patent Information
- Application Number
- CN202611335067.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-31
- Publication Date
- 2026-11-03
AI Technical Summary
Severe burn wounds are prone to infection, and current antibiotic treatments are not ideal, failing to effectively improve the wound microenvironment and promote healing, and are also prone to causing dysbiosis and drug resistance.
Lactobacillus acidipiscis JZG-1 and its metabolites were used to regulate the microbial community structure and promote wound healing by being applied directly to the wound surface. The treatment was combined with Phellodendron amurense solution to enhance the effect.
It effectively inhibits the growth of pathogenic bacteria, promotes skin wound healing, improves the microenvironment, increases wound healing rate, and reduces scar formation.
Smart Images
Figure CN123027152A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a strain of Lactobacillus acidophilus and its application in wound healing, belonging to the field of microbial technology. Background Technology
[0002] Burns, as a common and complex type of trauma, are characterized by diverse and severe pathophysiological changes. The healing process is often slower than other wounds and is prone to complications such as infection and scar formation, significantly impacting patients' functional recovery and quality of life. The healing process of burn wounds involves several interconnected and overlapping phases, primarily including the inflammatory response, the proliferative phase, and the remodeling phase. During the inflammatory phase, damaged tissue clears pathogens and necrotic tissue through the recruitment and activation of immune cells. The proliferative phase focuses on cell migration, proliferation, angiogenesis, and collagen deposition to fill the wound. The remodeling phase involves collagen reorganization and the restoration of skin structure, determining whether scarring will ultimately occur. However, due to factors such as injury depth, infection risk, and fluid imbalance, burn wounds often exhibit limited self-repair capabilities, excessive and prolonged inflammatory responses, leading to delayed healing and a significantly increased risk of hypertrophic scarring. Currently, for mild to moderate burns, due to the small area of damage and mild inflammation, wound repair can be achieved through dressing changes, coverage with biological dressings, or local skin grafting. Severe infections are rare, and the treatment process is relatively stable. However, for severe and extensive burns, clinical practice generally promotes wound healing through early and aggressive anti-shock measures, protection of vital organ function, infection control, timely and effective biological dressing coverage, multiple autologous skin repair surgeries, and nutritional support, thereby achieving successful treatment for patients with extensive burns.
[0003] Although clinical treatment involves aggressive methods such as debridement, skin grafting, and anti-infection therapy, burn infection remains a leading cause of death in patients with extensive burns. This is due to two main reasons: firstly, burns disrupt the skin barrier, leading to decreased local and systemic immunity and altering the wound's immune microenvironment, increasing susceptibility to various pathogens; secondly, the use of disinfectants and antibiotics only addresses the symptoms, not the root cause, failing to alter and regulate the wound's immune environment. Despite aggressive dressing changes, wound cleaning, and systemic and local antibiotic treatment, the effects are often unsatisfactory, with persistent positive wound and blood cultures and the presence of multidrug resistance, making eradication difficult and endangering the patient's life. Clinical data shows that common wound-infecting bacteria such as Staphylococcus aureus are highly susceptible to β-D-type infections. Resistance rates to lactam antibiotics have exceeded 60%, forcing the use of higher doses or broad-spectrum antibiotics in treatment. This not only increases the risk of liver and kidney toxicity but may also disrupt the wound microecological balance. Furthermore, antibiotics cannot directly promote key healing processes such as epithelial cell migration and angiogenesis, limiting their effectiveness in treating uninfected wounds.
[0004] Therefore, there is an urgent clinical need for a biological agent that has antibacterial and bacteriostatic effects and can promote wound healing. When used to treat burn wounds, it can not only effectively improve the disordered microenvironment of the wound and the problems of dysbiosis and drug resistance caused by the large amount and long-term use of antibiotics, but also has anti-inflammatory, antioxidant, melanin inhibition and moisturizing effects, which are conducive to promoting wound recovery and preventing scarring. Summary of the Invention
[0005] This invention provides a strain of Lactobacillus acidophilus ( Lactobacillus acidipiscis JZG-1, characterized in that the Lactobacillus acidophilus JZG-1 was deposited at the China Center for Type Culture Collection on February 4, 2026, with accession number CCTCC NO:M 2026337.
[0006] The present invention also provides a microbial agent containing the above-mentioned *Lactobacillus acidophilus* ( Lactobacillus acidipiscis JZG-1.
[0007] In one embodiment of the present invention, the microbial agent contains the *Lactobacillus acidophilus* ( Lactobacillus acidipiscis JZG-1 live cells and / or cell metabolites, and / or inactivated cells, and / or lyophilized cells.
[0008] In one embodiment of the present invention, the microbial agent contains *Lactobacillus acidophilus* ( Lactobacillus acidipiscis The quantity of JZG-1 is ≥ 1 × 10 6 CFU / mL or 1×10 6 CFU / g.
[0009] The present invention also provides a product containing the above-mentioned *Lactobacillus acidophilus* ( Lactobacillus acidipiscis JZG-1 or the above-mentioned microbial agents.
[0010] In one embodiment of the present invention, the product is food, medicine, or health product.
[0011] The present invention also provides a medicine for relieving and / or treating wound healing, said medicine containing the above-mentioned *Lactobacillus acidophilus* ( Lactobacillus acidipiscis JZG-1 or the above-mentioned microbial agents.
[0012] In one embodiment of the present invention, the pharmaceutical product further contains pharmaceutically acceptable excipients; the pharmaceutical excipients refer to conventional drug carriers in the pharmaceutical field.
[0013] In one embodiment of the present invention, the excipients include one or more of the following: binders such as cellulose derivatives, alginate, gelatin, and polyvinylpyrrolidone; diluents such as starch, pregelatinized starch, dextrin, sucrose, lactose, and mannitol; fillers such as starch and sucrose; humectants such as glycerin; disintegrants such as sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, and dry starch; absorption promoters such as quaternary ammonium compounds; surfactants such as polysorbate, fatty acid sorbitan, and fatty acid glycerides; colorants such as titanium dioxide, sunset yellow, methylene blue, and pharmaceutical iron oxide red; lubricants such as hydrogenated vegetable oil, talc, and polyethylene glycol; coating materials such as acrylic resin, hydroxypropyl methylcellulose, povidone, and cellulose acetate; and other excipients such as flavoring agents and sweeteners may also be added to the composition.
[0014] In one embodiment of the present invention, the dosage form of the drug includes, but is not limited to, oral dosage form, injection dosage form, and inhalation dosage form; In one embodiment of the present invention, the oral dosage form includes, but is not limited to, tablets, capsules, granules, oral liquids, and oral suspensions; In one embodiment of the present invention, the injectable dosage form includes, but is not limited to, an injection solution or an injection powder for injection; In one embodiment of the present invention, the inhalation dosage form includes, but is not limited to, aerosols and powder inhalers; In one embodiment of the present invention, the food includes, but is not limited to, grain products, vegetable products, fruit products, meat products, seafood, egg products, dairy products, soy products, and beverages; the food also includes special dietary foods; In one embodiment of the present invention, the health product also contains acceptable excipients.
[0015] The present invention also provides the above-mentioned Lactobacillus acidophilus ( Lactobacillus acidipiscis The use of JZG-1 or the above-mentioned microbial agents in the preparation of medicines for treating and / or alleviating wound healing.
[0016] In one embodiment of the present invention, the pharmaceutical product further contains pharmaceutically acceptable excipients; the pharmaceutical excipients refer to conventional drug carriers in the pharmaceutical field.
[0017] In one embodiment of the present invention, the excipients include one or more of the following: binders such as cellulose derivatives, alginate, gelatin, and polyvinylpyrrolidone; diluents such as starch, pregelatinized starch, dextrin, sucrose, lactose, and mannitol; fillers such as starch and sucrose; humectants such as glycerin; disintegrants such as sodium carboxymethyl starch, croscarmellose, and dry starch; absorption promoters such as quaternary ammonium compounds; surfactants such as polysorbate, fatty acid sorbitan, and fatty acid glycerides; colorants such as titanium dioxide, sunset yellow, methylene blue, and pharmaceutical iron oxide red; lubricants such as hydrogenated vegetable oil, talc, and polyethylene glycol; coating materials such as acrylic resin, hydroxypropyl methylcellulose, povidone, and cellulose acetate; and other excipients such as flavoring agents and sweeteners may also be added to the composition. In one embodiment of the present invention, the dosage form of the drug includes, but is not limited to, oral dosage form, injection dosage form, and inhalation dosage form; In one embodiment of the present invention, the oral dosage form includes, but is not limited to, tablets, capsules, granules, oral liquids, and oral suspensions; In one embodiment of the present invention, the injectable dosage form includes, but is not limited to, an injection solution or an injection powder for injection; In one embodiment of the present invention, the inhalation dosage form includes, but is not limited to, aerosols and powder inhalers.
[0018] Beneficial effects (1) The present invention uses the screened Lactobacillus acidophilus ( Lactobacillus acidipiscis JZG-1 can effectively inhibit pathogenic bacteria Escherichia coli (E. coli). E. coli Staphylococcus aureus S. aureus ) and Salmonella ( Salmonella ) growth.
[0019] (2) The Lactobacillus acidophilus provided by this invention ( Lactobacillus acidipiscis When JZG-1 is applied directly to the wound surface, its metabolites produced during its growth can promote skin wound healing. In addition, this bacterium may also promote wound healing by regulating the microbial community structure of the wound microenvironment.
[0020] (3) The Lactobacillus acidophilus provided by this invention ( Lactobacillus acidipiscis JZG-1 can promote the proliferation of Staphylococcus epidermidis.
[0021] Preservation of biological materials A strain of Lactobacillus acidophilus ( Lactobacillus acidipiscis JZG-1, taxonomically named Lactobacillus acidipiscis JZG-1 was deposited on February 4, 2026, at the China Center for Type Culture Collection (CCTCC) with accession number CCTCC NO: M 2026337, located at Wuhan University, Wuhan, China. Attached Figure Description
[0022] Figure 1 Wound healing status in the sterile saline group.
[0023] Figure 2 Wound healing status of groups treated with aseptic supernatant from Lactobacillus acidophilus JZG-1 fermentation.
[0024] Figure 3 Wound healing status of groups treated with Lactobacillus acidophilus JZG-1 fermentation broth.
[0025] Figure 4 Wound healing status of groups treated with sterile supernatant of Lactobacillus acidophilus JZG-1 fermentation + Phellodendron bark solution.
[0026] Figure 5 Wound healing status in groups treated with Lactobacillus acidophilus JZG-1 fermentation broth + Phellodendron bark solution.
[0027] Figure 6 Wound healing status of the Phellodendron bark solution group. Detailed Implementation
[0028] Unless otherwise specified, the techniques used in the examples are conventional techniques well known to those skilled in the art. Unless otherwise specified, the reagents used in the examples are commercially available.
[0029] The culture media involved in the following examples are as follows: MRS medium: 10.0 g peptone, 5.0 g beef extract, 4.0 g yeast extract, 20.0 g glucose, 2.0 g dipotassium hydrogen phosphate, 2.0 g triammonium citrate, 5.0 g sodium acetate, 0.2 g magnesium sulfate, 0.05 g manganese sulfate, 1.0 g Tween 80, 15-20 g agar, 1000 mL distilled water, pH 6.2±0.2, sterilized at 121℃ for 20 min.
[0030] LB medium: Add 10g tryptone, 5g yeast extract and 10g sodium chloride per liter of solvent, adjust the pH to 7.0 and then sterilize at 121℃.
[0031] BHI liquid culture medium ( / L): tryptone 10.0g, ox heart extract 17.5g, sodium chloride 5.0g, glucose 2.0g, disodium hydrogen phosphate (12H2O) 2.5g TSB liquid medium: tryptone 17g / L, soybean peptone 3g / L, sodium chloride 5g / L, glucose 2.5g / L.
[0032] The pathogenic bacteria involved in the following examples—Enterococcus faecalis, Staphylococcus aureus, Stenotrophomonas maltophilia, Corynebacterium banding, Pseudomonas aeruginosa, Aeromonas hydrophila, Acinetobacter baumannii, Proteus mirabilis, Staphylococcus aureus, Staphylococcus hemolyticus, Staphylococcus aureus, Aspergillus flavus, and Candida tropicalis—were screened by the inventors and are stored in the testing center of the Affiliated Hospital of Jiangnan University.
[0033] The HFF cells involved in the following examples are commercially available products that can be purchased or prepared by isolation.
[0034] Example 1: Isolation and Identification of Lactobacillus acidophilus 1. Obtaining the strain Naturally fermented kimchi was added to sterile physiological saline and shaken well. After serial dilution with physiological saline, the mixture was spread onto MRS agar plates, with three replicates for each dilution. The plates were then placed in an anaerobic chamber and incubated at 37°C for 32 h. Colonies showing significant differences were selected and streaked onto MRS solid agar plates for isolation. After anaerobic incubation at 37°C for 32 h, this process was repeated 3-5 times. Single colonies were then selected for hydrogen peroxide titration. A positive catalase test was indicated by the formation of bubbles on a slide containing 8% hydrogen peroxide solution, while a negative test was indicated by the absence of bubbles.
[0035] 2. Identification of lactic acid bacteria: The genome of the strain was extracted, amplified with 16S rDNA, and sequenced (performed by Suzhou Genewiz Biotechnology Co., Ltd.). The results, confirmed by NCBI sequence alignment, identified it as *Lactobacillus acidophilus*. Lactobacillus acidipiscis The obtained Lactobacillus acidophilus ( Lactobacillus acidipiscis JZG-1 was deposited at the China Center for Type Culture Collection on February 4, 2026, with accession number CCTCC NO: M 2026337.
[0036] Example 2: Performance testing of Lactobacillus acidophilus JZG-1 1. Preparation and antibacterial activity of Lactobacillus acidophilus JZG-1 fermentation broth (1) Preparation of sterile supernatant and fermentation broth from Lactobacillus acidophilus JZG-1 fermentation Preparation of sterile supernatant from Lactobacillus acidophilus fermentation: Activated Lactobacillus acidophilus JZG-1 bacterial culture was transferred to MRS liquid medium at an inoculation rate of 10% (v / v) and incubated at 37℃ for 16 h to obtain the fermentation broth (bacterial concentration: 5 × 10⁻⁶). 8 (CFU / mL), centrifuge to collect the supernatant, and filter through a 0.22μm filter membrane to obtain a sterile supernatant sample of Lactobacillus acidophilus; Preparation of *Lactobacillus acidophilus* fermentation broth: Activated *Lactobacillus acidophilus* JZG-1 bacterial suspension was transferred to MRS liquid medium at an inoculation rate of 10% (v / v) and incubated at 37℃ for 16 h to obtain the *Lactobacillus acidophilus* fermentation broth (bacterial concentration: 5 × 10⁻⁶). 8 (CFU / mL) (2) Preparation of pathogenic bacteria suspension Pathogenic bacteria (Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, Proteus mirabilis, Staphylococcus aureus, Staphylococcus hominis, and Staphylococcus hemolyticus) were inoculated into LB agar medium at 37°C and activated for 16 hours. Single colonies were picked and inoculated into LB liquid medium and cultured for another 16 hours in a shaker at 37°C (200 rpm) to prepare bacterial suspensions. The bacterial suspensions were then diluted with fresh LB medium to adjust the cell concentration to 1 × 10⁻⁶. 6 CFU / mL was used to obtain a bacterial suspension for antibacterial testing. The pathogenic bacterium *Aeromonas hydrophila* was inoculated into LB agar medium at 28°C and cultured for 16 hours to activate it. Single colonies were then picked and inoculated into LB liquid medium, and cultured for another 16 hours at 28°C on a shaker (200 rpm) to prepare a bacterial suspension. The suspension was then diluted with fresh LB medium to adjust the cell concentration to 1 × 10⁻⁶ cells / mL. 6 CFU / mL was used to obtain a bacterial suspension for antibacterial testing. The pathogenic bacterium *Enterococcus faecalis* was inoculated into MRS medium at 37°C and cultured for 16 hours. Single colonies were picked and inoculated into MRS liquid medium, and cultured for another 16-18 hours at 37°C on a shaker (200 rpm) to prepare the bacterial suspension. The bacterial suspension was then diluted with MRS medium to adjust the cell concentration to 1 × 10⁻⁶. 6 CFU / mL was used to obtain a bacterial suspension for antibacterial testing. Stenotrophomonas maltophilia was activated by inoculating it into trypsin-soybean agar (TSA) medium at 30°C for 16 hours. Single colonies were then picked and inoculated into TSA liquid medium and cultured at 30°C for 16 hours to prepare a bacterial suspension. The suspension was then diluted with TSA medium to adjust the cell concentration to 1 × 10⁻⁶. 6 CFU / mL was used to obtain a bacterial suspension for antibacterial testing. Aspergillus flavus was inoculated into PDA medium at 28°C and activated for 3–5 days. Single colonies were picked and inoculated into PDA liquid medium, and cultured at 28°C for another 24–36 hours to prepare a bacterial suspension. The bacterial suspension was then diluted with PDA medium to adjust the spore concentration to 1 × 10⁻⁶. 6CFU / mL was used to obtain a bacterial suspension for antibacterial testing. Candida tropicalis was inoculated into YPD medium at 30°C and cultured for 24 hours to activate it. Single colonies were then picked and inoculated into YPD liquid medium, and cultured for another 24 hours at 30°C to prepare a bacterial suspension. The bacterial suspension was then diluted with YPD medium to adjust the cell concentration to 1 × 10⁻⁶. 6 CFU / mL was used to obtain a bacterial suspension for antibacterial testing. (3) Antibacterial test: The above-mentioned bacterial pathogens were selected to evaluate the antibacterial spectrum of Lactobacillus acidophilus obtained in Example 1.
[0037] Take 100 μL of bacterial suspension and spread it on the corresponding solid culture medium. Then, punch holes in the culture medium and add 50 μL of the two samples from step (1) (sterile supernatant sample of Lactobacillus acidophilus and fermentation broth of Lactobacillus acidophilus) to each well. Incubate at 37℃ for 16 h. The results showed that *Lactobacillus acidophilus* had significant antibacterial properties against *Stenotrophomonas maltophilia*, *Aeromonas hydrophila*, and *Staphylococcus aureus*.
[0038] However, it does not have antibacterial properties against Enterococcus faecalis, Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, Proteus mirabilis, Staphylococcus hemolyticus, Staphylococcus aureus, Aspergillus flavus, and Candida tropicalis.
[0039] 2. Effects of Lactobacillus acidophilus JZG-1 on the proliferation capacity of normal HFF cells A proliferation experiment was conducted to analyze the proliferative capacity of HFF cells treated with *Lactobacillus acidophilus*. The specific experimental steps were as follows: HFF cells in the logarithmic growth phase were digested with trypsin and resuspended in complete culture medium to form a single-cell suspension. Cell counting was performed, and the cell concentration was adjusted to 1×10⁻⁶. 5 Cells / mL, add 100 μL of cell suspension to each well of a 96-well plate; incubate at 37°C and 5% CO2 for 24 h until the cells adhere, then carefully aspirate the original culture medium; They were randomly divided into four groups, as follows: Control group: 100 μL of fresh, complete culture medium, cell-free; Control group: 100 μL of fresh complete culture medium was added to the above well plates containing HFF cells; Experimental group 1: The sterile supernatant of Lactobacillus fermentation prepared in step 1 was mixed with the complete culture medium at a volume ratio of 1:10, and then 100 μL was added to the well plate containing HFF cells. Experimental group 2: The fermentation broth of Lactobacillus acidophilus prepared in step 1 was mixed with the complete culture medium at a volume ratio of 1:10, and then 100 μL was added to the well plate containing HFF cells. Return the culture plate to the incubator and continue culturing for 48 hours. Add 10 μL of CCK-8 solution to each well and incubate in the dark for 1-4 hours. Observe under a microscope during this period. Stop culturing when the solution in the control group wells turns a distinct orange-red color. Use a microplate reader to measure the absorbance of each well at a wavelength of 450 nm; calculate the average OD value of each replicate group.
[0040] Cell viability (%) = (OD experimental group - OD blank group) / (OD control group - OD blank group) × 100%.
[0041] The results showed that, compared with the control group, the sterile supernatant of Lactobacillus acidophilus fermentation increased the cell viability of HFF cells by 25%; the fermentation broth of Lactobacillus acidophilus increased the cell viability of HFF cells by 37%.
[0042] It is evident that both the sterile supernatant and the fermentation broth of *Lactobacillus tamarindus* can inhibit the proliferation of normal HFF cells.
[0043] 3. Co-culturing with Staphylococcus epidermidis promotes the proliferation of Staphylococcus epidermidis. The specific steps are as follows: (1) Preparation of Lactobacillus acidophilus JZG-1 seed culture: Lactobacillus acidophilus was inoculated into MRS liquid medium and cultured at 37°C for 24 h to prepare an activated solution. The prepared activation solution was transferred to MRS liquid medium at an inoculation rate of 10% (v / v) and incubated at 37°C for 12 h to obtain the seed solution. (2) Preparation of Staphylococcus epidermidis seed culture: Staphylococcus epidermidis was inoculated into TSB liquid medium and incubated at 37°C for 48 h to prepare an activated solution. The prepared activation solution was transferred to TSB liquid medium at an inoculation rate of 10% (v / v) and incubated at 37°C for 48 h to obtain seed culture. (3) Co-fermentation culture Control group 1 (Lactobacillus acidophilus JZG-1): The Lactobacillus acidophilus seed culture obtained in step (1) was inoculated into 100 ml of pre-distilled MRS liquid medium at an inoculation rate of 10% (v / v) for fermentation under the following conditions: 37℃ incubator for 24 h. Control group 2 (Staphylococcus epidermidis): The Staphylococcus epidermidis seed culture obtained in step (2) was inoculated at an inoculation rate of 10% (v / v) into 100 ml of pre-amplified MRS liquid medium for fermentation under the following conditions: 37℃ incubator for 24 h. Co-culture group (Lactobacillus acidophilus JZG-1 + Staphylococcus epidermidis): The Lactobacillus acidophilus seed liquid obtained in step (1) and the Staphylococcus epidermidis seed liquid obtained in step (2) were inoculated into 100 ml of MRS liquid medium in a ratio of 1:1 and a total inoculation amount of 10% (v / v) for fermentation. The conditions were: 37℃ incubator for 24 h. The OD600 of each group at the fermentation endpoint was measured separately.
[0044] The results showed that the OD600 in the co-culture group was 2.6 times that of control group 1 and 2.8 times that of control group 2. Among them, the biomass of Staphylococcus epidermidis was higher than that of Lactobacillus acidophilus in the co-culture group. Therefore, Lactobacillus acidophilus can promote the proliferation of Staphylococcus epidermidis.
[0045] Example 4: Animal experiment on the combined use of probiotics and probiotic Phellodendron amurense to promote wound healing. The liquid fermentation broth preparation of *Lactobacillus acidophilus* of the present invention was dripped onto the burn infection wound to verify that *Lactobacillus acidophilus* of the present invention can alleviate skin damage caused by burn infection and promote the healing of infected wounds.
[0046] All animals were housed in a specific pathogen-free (SPF) animal facility. Throughout the trial, all animals were maintained in the same standard environment (23...). 26℃, 40 60% humidity, 12 hours of light Dark cycle (five mice / cage). All procedures, including animal care, wound modeling, drug administration, and termination, were performed in accordance with the Animal Welfare and Ethics Review Guidelines for Laboratory Animals. Mice were anesthetized with isoflurane before any painful procedures. Mice were euthanized with chloral hydrate at the end of the experiment.
[0047] 1. Solution preparation (1) Preparation of sterile supernatant from Lactobacillus acidophilus JZG-1 fermentation: The activated Lactobacillus acidophilus culture was transferred to MRS liquid medium at an inoculation rate of 10% (v / v) and incubated at 37℃ for 16 h to obtain the fermentation broth (crystal concentration: 5×10⁻⁶). 8 (CFU / mL), centrifuge to collect the supernatant, and filter through a 0.22 μm filter membrane to obtain a sterile supernatant sample of Lactobacillus acidophilus; (2) Preparation of Lactobacillus acidophilus JZG-1 fermentation broth: The activated Lactobacillus acidophilus broth was transferred to MRS liquid medium at an inoculation rate of 10% (v / v) and incubated at 37℃ for 16 h to obtain Lactobacillus acidophilus fermentation broth (bacterial concentration: 5×10⁻⁶). 8 (CFU / mL) (3) Preparation of Phellodendron bark solution Dissolve Phellodendron bark powder in water, and calculate the content of berberine hydrochloride in the solution as 10 g / L, thus obtaining the Phellodendron bark solution.
[0048] (4) Sterile supernatant of Lactobacillus acidophilus JZG-1 fermentation + Phellodendron bark solution: The sterile supernatant of Lactobacillus acidophilus fermentation prepared in step (1) and the Phellodendron bark solution were mixed in a volume ratio of 1:1; (5) Lactobacillus acidophilus JZG-1 fermentation broth + Phellodendron amurense solution: The Lactobacillus acidophilus fermentation broth and Phellodendron amurense solution prepared in step (2) are mixed in a volume ratio of 1:1; 2. Experimental animals and grouping Eight-week-old male SD rats were randomly divided into four groups of four. The fur on the backs of all rats was shaved, and any remaining hair was completely removed after applying depilatory cream for 10 minutes. Twenty-four hours after depilation, the rats were anesthetized with isoflurane. A square, full-thickness wound with approximately 10 mm sides was then created on the back of each rat, according to the groupings in Table 1. Table 1: Grouping
[0049] Specifically: Group A: Add 0.5 ml of sterile saline solution; Group B: Add 0.5 ml of sterile supernatant from Lactobacillus acidophilus fermentation; Group C: Add 0.5 ml of Lactobacillus acidophilus fermentation solution; Group D: Add 0.5 ml of sterile supernatant from Lactobacillus acidophilus fermentation + Phellodendron bark solution; Group E: Add 0.5 ml of Lactobacillus acidophilus fermentation liquid + Phellodendron bark solution; Group F: Add 0.5 ml of Phellodendron bark solution.
[0050] Wrap the wound with gauze, change the sample solution daily, and take photos to record the wound healing process; The experiment lasted for 10 days; on the 10th day, Group A ( Figure 1 Group B Figure 2 Group C Figure 3 Group D Figure 4 Group E Figure 5 Group F Figure 6The skin of the five groups of rats was basically healed, with healing rates of 80.47%, 84.85%, 86.82%, 95.86%, 96.67%, and 81.15%, respectively.
[0051] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be determined by the claims.
Claims
1. A strain of Lactobacillus acidophilus ( Lactobacillus acidipiscis JZG-1, characterized in that, The Lactobacillus acidophilus was deposited at the China Center for Type Culture Collection on February 4, 2026, with accession number CCTCC NO: M2026337.
2. A microbial inoculant, characterized in that, The microbial agent contains *Lactobacillus acidophilus* JZG-1 as described in claim 1.
3. The microbial agent according to claim 2, characterized in that, The microbial agent contains live cells and / or cell metabolites of *Lactobacillus acidophilus* JZG-1, and / or inactivated cells, and / or freeze-dried cells.
4. The microbial agent according to claim 2 or 3, characterized in that, The number of *Lactobacillus acidophilus* JZG-1 in the microbial agent is ≥1×10⁻⁶. 6 CFU / mL or 1×10 6 CFU / g.
5. A product characterized in that, The product contains the Lactobacillus acidophilus of claim 1 or any of the microbial agents of claims 2 to 4.
6. The product according to claim 5, characterized in that, The product in question is food, medicine, or health supplement.
7. The product according to claim 6, characterized in that, The drug also contains pharmaceutically acceptable excipients; the excipients refer to conventional drug carriers in the pharmaceutical field. Preferably, the excipients include one or more of the following: binders such as cellulose derivatives, alginate, gelatin, and polyvinylpyrrolidone; diluents such as starch, pregelatinized starch, dextrin, sucrose, lactose, and mannitol; fillers such as starch and sucrose; humectants such as glycerin; disintegrants such as sodium carboxymethyl starch, croscarmellose, and dry starch; absorption promoters such as quaternary ammonium compounds; surfactants such as polysorbate, fatty acid sorbitan, and fatty acid glycerides; colorants such as titanium dioxide, sunset yellow, methylene blue, and pharmaceutical iron oxide red; lubricants such as hydrogenated vegetable oil, talc, and polyethylene glycol; coating materials such as acrylic resin, hydroxypropyl methylcellulose, povidone, and cellulose acetate; and other excipients such as flavoring agents and sweeteners may also be added to the composition. Preferably, the dosage form of the drug includes, but is not limited to, oral dosage form, injection dosage form, and inhalation dosage form; Preferably, the oral dosage form includes, but is not limited to, tablets, capsules, granules, oral liquids, and oral suspensions; Preferably, the injectable dosage form includes, but is not limited to, injection solution and injection powder for injection; Preferably, the inhalation dosage form includes, but is not limited to, aerosols and powder inhalers; Preferably, the food includes, but is not limited to, grain products, vegetable products, fruit products, meat products, seafood, egg products, dairy products, soy products, and beverages; the food also includes special dietary foods. Preferably, the health product also contains acceptable excipients.
8. The use of Lactobacillus acidophilus JZG-1 as described in claim 1 or any of the microbial agents described in claims 2 to 4 in the preparation of medicines for treating and / or alleviating wound healing.
9. The application according to claim 9, characterized in that, The drug also contains pharmaceutically acceptable excipients; the excipients refer to conventional drug carriers in the pharmaceutical field.
10. The application according to claim 8 or 9, characterized in that, The excipients include one or more of the following: binders such as cellulose derivatives, alginate, gelatin, and polyvinylpyrrolidone; diluents such as starch, pregelatinized starch, dextrin, sucrose, lactose, and mannitol; fillers such as starch and sucrose; humectants such as glycerin; disintegrants such as sodium carboxymethyl starch, croscarmellose, and dry starch; absorption promoters such as quaternary ammonium compounds; surfactants such as polysorbate, fatty acid sorbitan, and fatty acid glycerides; colorants such as titanium dioxide, sunset yellow, methylene blue, and pharmaceutical iron oxide red; lubricants such as hydrogenated vegetable oil, talc, and polyethylene glycol; coating materials such as acrylic resin, hydroxypropyl methylcellulose, povidone, and cellulose acetate; and other excipients such as flavoring agents and sweeteners may also be added to the composition. Preferably, the dosage form of the drug includes, but is not limited to, oral dosage form, injection dosage form, and inhalation dosage form; Preferably, the oral dosage form includes, but is not limited to, tablets, capsules, granules, oral liquids, and oral suspensions; Preferably, the injectable dosage form includes, but is not limited to, injection solution and injection powder for injection; Preferably, the inhalation dosage form includes, but is not limited to, aerosols and powder inhalers.